Browsing Category
Pharma Industry News
4739 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Why Viking Therapeutics (NASDAQ: VKTX) is gaining momentum before ObesityWeek 2025 reveals
Find out how Viking Therapeutics is positioning its obesity drug VK2735 for success as it readies data reveals at major 2025 medical conferences.
Is Johnson & Johnson quietly building a new autoimmune franchise around FcRn inhibition?
Johnson & Johnson is expanding nipocalimab into multiple autoimmune indications. Find out if FcRn inhibition is the foundation of its next blockbuster franchise.
GSK’s B7-H3 ADC secures EU orphan drug status as it accelerates global lung cancer trials
GSK’s B7-H3-targeted ADC GSK’227 receives EU Orphan Drug Designation for small-cell lung cancer. Learn how it fits into the company’s expanding global trial program.
Can Piramal Pharma Solutions’ ADCelerate platform gain an edge with IntoCell’s linker-payload tech?
Piramal Pharma Solutions teams up with IntoCell to expand ADCelerate platform and access cutting-edge linker-payload tech. Explore how this reshapes the CDMO landscape.
Why Thermo Fisher Scientific (NASDAQ: TMO) is spending US$9.4bn on Clario to dominate clinical-trial analytics
Find out how Thermo Fisher’s US$9.4 billion acquisition of Clario is reshaping the clinical-trial services industry and what it means for investors.
Is Ernexa Therapeutics (NASDAQ: ERNA) turning into the next small‑cap biotech breakout?
Is Ernexa Therapeutics (NASDAQ: ERNA) the next small-cap biotech breakout? Learn how its iMSC platform and Cellipont partnership could change its trajectory.
How the UK’s £55bn R&D funding plan aims to transform health, AI, and clean energy sectors
UK confirms £55B R&D funding through 2030 to power innovation in AI, health, and clean energy. Find out how this public investment could reshape UK industry.
Savara’s $130m stock offering strengthens cash position ahead of MOLBREEVI launch
Savara raises $130 million through stock and warrant sale to fund MOLBREEVI’s rare-disease launch—find out how this deal reshapes its commercialization path.
Is GSK stock gearing up for a breakout? Q3 2025 results beat, guidance raised, CEO exits on a high
GSK upgrades 2025 guidance after strong Q3 results, driving a 6.57% stock surge. Find out how Specialty Medicines and Oncology powered this breakout.
NLS Pharmaceutics and Kadimastem merger gains BIRD Foundation boost for breakthrough Type 1 diabetes therapy
Discover how NLS Pharmaceutics and Kadimastem’s merger, backed by renewed BIRD Foundation funding, positions NewCelX to challenge global leaders in diabetes cell therapy.